<div><p>During the past decade, the dual function of the immune system in tumor inhibition and tumor progression has become appreciated. We have previously reported that neu-specific T cells can induce rejection of neu positive mouse mammary carcinoma (MMC) and also facilitate tumor relapse by inducing neu antigen loss and epithelial to mesenchymal transition (EMT). Here, we sought to determine the mechanism by which CD8+ T cells either eliminate the tumor, or maintain tumor cells in a dormant state and eventually facilitate tumor relapse. We show that tumor cells that express high levels of IFN-γ Rα are eliminated by CD8+ T cells. In contrast, tumor cells that express low levels of IFN-γ Rα do not die but remain dormant and quiescent in th...
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by inco...
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by inco...
textabstractClinical therapy with T cells shows promise for cancer patients, but is currently challe...
During the past decade, the dual function of the immune system in tumor inhibition and tumor progres...
Tumor-reactive T lymphocytes can direct the progression of tumor immunity through the secretion of c...
Background Tumor relapse constitutes a major challenge for anti-tumoral treatments, including immuno...
CD8+ effector T cells recognize malignant cells by monitoring their surface for the presence of tumo...
Effective antitumor CD8 T cell responses may be activated by directly targeting the innate immune sy...
Immune checkpoint blockade (ICB) provides clinical benefit to a minority of patients with urothelial...
Genetic evolution that occurs during cancer progression enables tumour heterogeneity, thereby foster...
Despite lack of tumor control in many models, spontaneous T cell priming occurs frequently in respon...
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shape...
International audienceAbstract CD4 + T cells and CD4 + chimeric antigen receptor (CAR) T cells displ...
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shape...
Genetic evolution that occurs during cancer progression enables tumour heterogeneity, thereby foster...
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by inco...
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by inco...
textabstractClinical therapy with T cells shows promise for cancer patients, but is currently challe...
During the past decade, the dual function of the immune system in tumor inhibition and tumor progres...
Tumor-reactive T lymphocytes can direct the progression of tumor immunity through the secretion of c...
Background Tumor relapse constitutes a major challenge for anti-tumoral treatments, including immuno...
CD8+ effector T cells recognize malignant cells by monitoring their surface for the presence of tumo...
Effective antitumor CD8 T cell responses may be activated by directly targeting the innate immune sy...
Immune checkpoint blockade (ICB) provides clinical benefit to a minority of patients with urothelial...
Genetic evolution that occurs during cancer progression enables tumour heterogeneity, thereby foster...
Despite lack of tumor control in many models, spontaneous T cell priming occurs frequently in respon...
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shape...
International audienceAbstract CD4 + T cells and CD4 + chimeric antigen receptor (CAR) T cells displ...
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shape...
Genetic evolution that occurs during cancer progression enables tumour heterogeneity, thereby foster...
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by inco...
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by inco...
textabstractClinical therapy with T cells shows promise for cancer patients, but is currently challe...